Sequoia Financial Advisors LLC Invests $700,000 in Stereotaxis Inc. $STXS

Sequoia Financial Advisors LLC acquired a new position in Stereotaxis Inc. (NYSEAMERICAN:STXS) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 380,652 shares of the company’s stock, valued at approximately $700,000.

Several other large investors have also added to or reduced their stakes in the business. WealthPLAN Partners LLC acquired a new position in Stereotaxis during the fourth quarter worth $29,000. SG Americas Securities LLC acquired a new stake in Stereotaxis in the 4th quarter valued at $33,000. BNP Paribas Financial Markets lifted its position in Stereotaxis by 106.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock worth $36,000 after buying an additional 5,910 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in Stereotaxis during the 3rd quarter worth about $38,000. Finally, HRT Financial LP acquired a new position in shares of Stereotaxis during the 4th quarter worth about $42,000. Institutional investors and hedge funds own 45.35% of the company’s stock.

Stereotaxis Stock Performance

Shares of NYSEAMERICAN STXS opened at $1.55 on Monday. Stereotaxis Inc. has a 52 week low of $1.46 and a 52 week high of $3.59. The stock has a market capitalization of $151.79 million, a P/E ratio of -6.46 and a beta of 1.34. The stock’s fifty day moving average is $1.81 and its 200 day moving average is $2.01.

Wall Street Analyst Weigh In

STXS has been the subject of several analyst reports. Citigroup restated a “market outperform” rating on shares of Stereotaxis in a report on Wednesday, June 3rd. Piper Sandler reiterated an “overweight” rating and set a $3.50 price objective (down from $4.00) on shares of Stereotaxis in a research report on Wednesday, May 13th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $3.88.

Stereotaxis Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.